Retatrutide TRIUMPH-4 Results: 28.7% Weight Loss Across a Diverse Trial Population
The retatrutide TRIUMPH-4 trial reported 28.7% mean weight loss — 71.2 lbs over 68 weeks at 12 mg — with consistent efficacy across demographic subgroups. The published data, broken down.
The Headline Numbers
TRIUMPH-4 is the retatrutide phase 3 results set that reset the pharmacotherapy ceiling: a reported mean of 28.7 percent weight loss — 71.2 lbs from a 248.5 lb baseline — over 68 weeks, with 12 mg as the trial's highest reported dose step. In the published comparisons that is the highest average weight loss recorded in an obesity drug trial, exceeding tirzepatide's 22.5% (SURMOUNT-1) and semaglutide's ~15% (STEP-1) at comparable endpoints.
The reported dose ladder matters for reading the data: the trial protocol escalated participants through 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg in roughly 4-week steps. Efficacy tracked those reported steps — lower reported steps delivered proportionally less, and the arm receiving the highest reported dose step carried both the best results and the most side-effect weeks during escalation.
Why the Diverse Population Design Matters
Earlier incretin trials were criticized for under-representing the populations most affected by obesity. The retatrutide diverse population trial enrolled deliberately broad demographics — across age bands, sex, race and ethnicity subgroups — and the sub-analyses reported the headline finding held with remarkable consistency: no subgroup lost dramatically less than the mean.
That consistency matters to the research literature. In a 58-year-old woman or a 32-year-old man, the trial data reported the same mechanism at work — GLP-1 appetite suppression, GIP insulin sensitization, glucagon-driven energy expenditure — across that range. Individual response still varies (trial means hide distributions), but subgroup efficacy gaps that appeared in older therapies were not present at meaningful scale.
The diverse-population design also shapes regulatory expectations: consistent subgroup data is exactly what FDA reviewers look for in an approval package, and the published commentary reads it as keeping retatrutide's approval timeline on the optimistic end of projections.
Safety, Access, and What the Published Data Reports
TRIUMPH-4's safety profile matched the incretin class: transient GI effects (nausea, vomiting, diarrhea) clustered in the escalation weeks, plus glucagon-mediated resting heart rate elevation of a few BPM that tapered with time. No new safety signals emerged at the highest reported dose step.
The access reality in 2026: retatrutide is NOT FDA-approved, and FDA has stated it cannot be lawfully compounded under 503A/503B. Trial enrollment is the only sanctioned access channel. Gray-market 'retatrutide' circulates with zero purity verification — our vendor database tracks which suppliers provide real third-party COAs.
The retatrutide 71 lbs weight loss figure and the full reported dose set are the endpoints researchers cite; our calculator performs concentration and volume conversions for reported research quantities only, and the research overview collects the published escalation data and mechanism findings in one place.
Retatrutide is investigational. It is not approved for human use by any regulator, no approved dosing exists, and the amounts above are reported from published trial protocols as research data — not as a schedule for anyone to follow.
📊 Dosage Calculator & Protocol Chart
Convert reported trial amounts into solution volumes for lab reference:
👉 Retatrutide Calculator — Concentration and volume conversions for reported research quantities.
👉 Full Retatrutide Research Overview — The published trial data, reported dose steps, and body-composition sub-study findings in one place.
Important Disclaimer
This article is for educational and research purposes only. Retatrutide is investigational and has not been approved by the FDA or any other regulator for human use. Peptides discussed may not be FDA-approved for all uses described. The information provided here is synthesized from published research, clinical trial data, and community discussions. Nothing on this page is medical advice, and no peptide discussed here is offered for human use.
Keywords: retatrutide TRIUMPH-4, 28.7 percent weight loss, retatrutide phase 3 results, retatrutide diverse population trial, retatrutide 71 lbs weight loss
Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content